Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
The companies’ decision to start a 1,500-patient Alzheimer’s disease study defies logic.
In the Keynote-426 study Merck & Co’s Keytruda looks to have blasted Opdivo out of the water, showing a 47% reduction in risk of death versus Sutent.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.